As individuals age, cNFs grow in size and number, and disfigurement resulting in emotional suffering from stigma and self-imposed social isolation. NF1 disease visibility has been associated with psychiatric morbidity, and depression. 

With the use of laser, electrodessication, surgical excision and, recent developments in the use of topical treatments for CNFs, there is a need to establish internationally standardised measures of treatment success. 

RNSH have partnered with Johns Hopkins University and Henri Mondor Hospital in Paris to develop and test outcomes for CNF treatment. These protocols will enable assessment of new therapies as they emerge (e.g., therapeutics, devices or drug treatments). This presentation will focus on current and emerging CNF therapies and outcome measures